Journal: Journal of Clinical Medicine

Article Title: Early Cellular and Humoral Responses Developed in Oncohematological Patients after Vaccination with One Dose against COVID-19

doi: 10.3390/jcm11102803

Figure Lengend Snippet: DCC and viral neutralization activity against SARS-CoV-2 infected cells of PBMCs of individuals with OHD before and after receiving one-dose vaccine. ( A ) The capacity of PBMCs from individuals with OHD to eliminate SARS-CoV-2-infected Vero E6 cells was determined by quantifying the production of Renilla (RLUs) after co-culture for 1 h. ( B ) DCC was assessed by measuring the activity of caspasa-3 in SARS-CoV-2-infected Vero E6 cells co-cultured with PBMCs from individuals with OHD, in comparison with healthy donors. Each dot in the graphs corresponds to mean ± SEM. Statistical significance between groups was calculated using one-way ANOVA test.

Article Snippet: Vero E6 (African green monkey kidney) cell line (ECACC 85020206) was kindly provided by Dr. Antonio Alcami (CBM Severo Ochoa, Madrid, Spain).

Techniques: Neutralization, Activity Assay, Infection, Co-Culture Assay, Cell Culture, Comparison

Journal: Journal of medical virology

Article Title: Neutralizing antibody response after immunization with a COVID-19 bivalent vaccine: Insights to the future.

doi: 10.1002/jmv.29416

Figure Lengend Snippet: FIGURE 2 Neutralization titer according to SARS‐CoV‐2 strain. Neutralization assays using the wild‐type SARS‐CoV‐2, the original Omicron variant (BA.1), and its subvariants FE.1.2 or BQ.1.1 were carried out. In brief, cell monolayers (5 × 104 Vero CCL‐81 cells/well) in 96‐well culture plates were exposed to 1 × 103 TCID50/mL of SARS‐CoV‐2 Wuhan strain—wild type or Omicron subvariants (BA.1, FE.1.2, BQ.1.1) that were previously incubated with 1:20–1:1280 twofold diluted, heat‐inactivated human serum samples, in a final volume of 150 µL. After 72 h of incubation, the plates were evaluated microscopically for the presence of characteristic SARS‐CoV‐2 CPEs. The absence of CPEs in the 1:20 diluted sample was considered a positive result for the presence of neutralizing antibodies against SARS‐CoV‐2. Comparisons between neutralization titers measured in samples from individuals immunized only with monovalent vaccines and those who received a booster shot with the bivalent vaccine are shown with regard to the wild‐type SARS‐CoV‐2 (A), Omicron BA.1 (B) and its subvariants FE.1.2 (C), and BQ.1.1 (D). In addition, neutralization titers with regard to each SARS‐CoV‐2 strain were compared considering values of samples from volunteers immunized only with monovalent vaccines (E) or those who received a booster shot with the bivalent vaccine (F). Statistical significance was set as p ≤0.05. *p ≤0.05; **p ≤0.01; ***p ≤0.001; ****p ≤0.0001. CPEs, cytopathic effects; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; TCID, tissue culture infectious dose.

Article Snippet: African Green monkey kidney cells Vero E6 (ATCC® CRL‐1586TM) and Vero CCL‐81 (ATCC® CCL‐81) were maintained according to the recommendations of ATCC®.

Techniques: Neutralization, Variant Assay, Incubation, Vaccines

Journal: Vaccines

Article Title: Development of an Inactivated Vaccine against SARS CoV-2

doi: 10.3390/vaccines9111266

Figure Lengend Snippet: Preparation of ERUCoV-VAC. ( a ) The viral kinetics of the hCoV-19/Turkey/ERAGEM-001/2020 strain at different multiplicities of infection (MOI). ( b ) Flowchart of ERUCoV-VAC preparation. ( c ) Protein profiles of the hCoV-19/Turkey/ERAGEM-001/2020 virus strain before and after purification. Total proteins were separated by Nu-page 10% bis-tris SDS-PAGE gel. Lane 1, protein molecular weight marker (M). Lane A, uninfected Vero E-6 cells as a negative control. Lane B, Vero E-6 cells infected with the hCoV-19/Turkey/ERAGEM-001/2020 virus strain. Lane C, purified hCoV-19/Turkey/ERAGEM-001/2020 virus strain. Western blot analysis of purified hCoV-19/Turkey/ERAGEM-001/2020 virus strain probed with a human antibody to the SARS-CoV-2 nucleocapsid protein (1:2500) (GenScript; HC2003) (Lane E) or a rabbit polyclonal to SARS-CoV-2 spike glycoprotein (lane G). Uninfected cell lysates probed with the SARS-CoV-2 nucleocapsid protein (Lane D) and a rabbit polyclonal to SARS-CoV-2 spike glycoprotein (F) were used as a negative control. The arrows indicate that the bands at approximately 180 kDa and 48 kDa represent spike glycoprotein and nucleocapsid protein, respectively.

Article Snippet: Vero E6 cells (African green monkey kidney) obtained from ATCC (CRL 1586) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 100 mM L-glutamine (Sigma–Aldrich, Darmstadt, Germany).

Techniques: Infection, Virus, Purification, SDS Page, Molecular Weight, Marker, Negative Control, Western Blot

Journal: Molecules

Article Title: Large Subunit of the Human Herpes Simplex Virus Terminase as a Promising Target in Design of Anti-Herpesvirus Agents

doi: 10.3390/molecules28217375

Figure Lengend Snippet: Sensitivity of progeny HSV-1/L 2 and compound 1 -resistant clones to a series of the approved antiherpetic agents * including drugs of practical importance in the Vero E6 cells.

Article Snippet: The Vero E6 (African green monkey ( Chlorocebus sabaeus ) kidney) cell culture was maintained by passaging in EMEM supplemented with 5% ( v / v ) fetal bovine serum (FBS) containing Hank’s salts, 2 mM L-glutamine, and 100 U/mL benzylpenicillin (PanEco, Moscow, Russia).

Techniques: Clone Assay